Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELICAN: PLD vs Capecitabine in Metastatic Breast Cancer
NCT00266799Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Primary completion
- Sep 2010
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Merck & Co.. Started Jan 2006; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00266799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266799.